Xiong H, Ni Z, He J, Jiang S, Li X, He J, Gong W, Zheng L, Chen S, Li B, Zhang N, Lyu X, Huang G, Chen B, Zhang Y, He F
Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China.
Battalion 17 of Students, College of Preventive Medicine, Third Military Medical University, Chongqing, China.
Oncogene. 2017 Jun 22;36(25):3528-3540. doi: 10.1038/onc.2016.521. Epub 2017 Feb 6.
Considerable evidences have shown that autophagy has an important role in tumor chemoresistance. However, it is still unknown whether the lncRNA HULC (highly upregulated in liver cancer) is involved in autophagy and chemoresistance of hepatocellular carcinoma (HCC). In this study, we for the first time demonstrated that treatment with antitumor reagents such as oxaliplatin, 5-fluorouracil and pirarubicin (THP) dramatically induced HULC expression and protective autophagy. Silencing of HULC sensitized HCC cells to the three antitumor reagents via inhibiting protective autophagy. Ectopic expression of HULC elicited the autophagy of HCC cells through stabilizing silent information regulator 1 (Sirt1) protein. The investigation for the corresponding mechanism by which HULC stabilized Sirt1 revealed that HULC upregulated ubiquitin-specific peptidase 22 (USP22), leading to the decrease of ubiquitin-mediated degradation of Sirt1 protein by removing the conjugated polyubiquitin chains from Sirt1. Moreover, we found that miR-6825-5p, miR-6845-5p and miR-6886-3p could decrease the level of USP22 protein by binding to the 3'-untranlated region of USP22 mRNA. All the three microRNAs (miRNAs) were downregulated by HULC, which resulted in the elevation of USP22. In addition, we showed that the level of HULC was positively correlated with that of Sirt1 protein in human HCC tissues. Collectively, our data reveals that the pathway 'HULC/USP22/Sirt1/ protective autophagy' attenuates the sensitivity of HCC cells to chemotherapeutic agents, suggesting that this pathway may be a novel target for developing sensitizing strategy to HCC chemotherapy.
大量证据表明自噬在肿瘤化疗耐药中起重要作用。然而,长链非编码RNA HULC(肝癌中高度上调)是否参与肝细胞癌(HCC)的自噬和化疗耐药仍不清楚。在本研究中,我们首次证明用奥沙利铂、5-氟尿嘧啶和吡柔比星(THP)等抗肿瘤试剂处理可显著诱导HULC表达和保护性自噬。沉默HULC通过抑制保护性自噬使HCC细胞对这三种抗肿瘤试剂敏感。HULC的异位表达通过稳定沉默信息调节因子1(Sirt1)蛋白引发HCC细胞自噬。对HULC稳定Sirt1的相应机制的研究表明,HULC上调泛素特异性肽酶22(USP22),通过从Sirt1上去除共轭多聚泛素链导致Sirt1蛋白泛素介导的降解减少。此外,我们发现miR-6825-5p、miR-6845-5p和miR-6886-3p可通过结合USP22 mRNA的3'非翻译区降低USP22蛋白水平。这三种微小RNA(miRNA)均被HULC下调,导致USP22升高。此外,我们表明在人HCC组织中HULC水平与Sirt1蛋白水平呈正相关。总体而言,我们的数据表明“HULC/USP22/Sirt1/保护性自噬”通路减弱了HCC细胞对化疗药物的敏感性,提示该通路可能是开发HCC化疗增敏策略的新靶点。